Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)

This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD). NSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form: Intervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing). Control group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.

NCT Number	NCT07343076
Lead Sponsor	RenJi Hospital Collaborators: People's Hospital of Xinjiang Uygur Autonomous Region, LanZhou University
Conditions	NSTEMI, NSTEMI - Non-ST Segment Elevation MI, Non-ST-elevation Acute Coronary Syndrome, NSTE-ACS (NSTEMI and UA)
Enrollment	1,904 participants
Start Date	2026-02-28
Primary Completion	2029-02-28 (estimated)
Study Completion	2031-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-30